Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 16/20 | 0.41 |
| ▸ | CDK2 | P24941 | 16/20 | 0.41 |
| ▸ | CCNK | O75909 | 16/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.41 |
| ▸ | CDK9 | P50750 | 15/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 8/20 | 0.37 |
| ▸ | CCNH | P51946 | 8/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25363465 | 1.00 | CCNE1 (0.41) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL30260889 | 0.91 | CCNK (0.40) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL26043873 | 0.89 | CCNE1 (0.39) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL25597105 | 0.89 | KDM4E (0.45) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL25362594 | 0.89 | CCNK (0.44) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL30456148 | 0.89 | CCNK (0.44) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL25597137 | 0.85 | CCNK (0.40) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL30260809 | 0.81 | CCNT1 (0.45) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL25362625 | 0.81 | CCNE1 (0.51) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL30456364 | 0.81 | CCNE1 (0.51) | CCNE1CDK2CCNKCDK12CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145632-A1 | Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine | INSILICO MEDICINE IP LIMITED (HK) | 2025-05-08 | — | — | US | disclosed |
| EP-4455132-A1 | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Insilico Medicine IP Limited (HK) | 2024-10-30 | — | — | EP | disclosed |
| CN-118647607-A | Pyrimidine heterocyclic compounds, process for preparing the same and pharmaceutical use thereof | 英矽智能科技(上海)有限公司 | 2024-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145632-A1 | Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine | DPYD, TYMP, NUDT1 | CCNE1 315/4885CDK2 73/4885CCNK 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.